Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis

Inclusion Criteria: * Willing to participate as indicated by providing written informed consent * 12 years of age or older, of any gender and any race * Have had a positive skin prick and/or intradermal test for a currently prevalent allergen within the past 5 years * A history of allergic rhinitis, for at least 2 years * Have undergone washout of all medications that could have an influence on the study * Willing and able to make required study visits * Able to follow instructions and record diary symptoms. * Free of significant anatomic abnormalities, infection, bleeding, and mucosal ulcerations on nasal examination * Have a TNSS between 4 and 12 averaged over the 7 days immediately prior to V2 * Have an average individual score for nasal congestion greater than or equal to 2 over the 7 days immediately prior to V2. Exclusion Criteria: * any concurrent disease that could interfere with the investigation or evaluation of the study medications such as: rhinitis medicamentosa or large obstructive nasal polyps * any other anatomic nasal deformity that could interfere with their participation in the study * asthma, with the exception of mild intermittent asthma * congestion that, in the opinion of the study investigator, could interfere with successful nasal drug administration/absorption (in either nostril) * use of systemic corticosteroids (oral, parenteral, intravenous, rectal) or inhaled or ocular corticosteroids within the last 30 days * be undergoing allergy immunotherapy, unless on a stable dosing regimen throughout the course of the study * Be using dermal potent or super-potent topical corticosteroids * any systemic disorder that could interfere with the evaluation of the study medication * hypersensitivity to the study drugs or any component thereof * history of drug or alcohol abuse that would interfere with participation in the study * history of severe, unstable, or uncontrolled cardiovascular, hepatic, renal and/or other diseases/illnesses that could be expected to interfere with the study * upper or lower respiratory infection within 14 days of Vist 2 * acute sinusitis within 30 days of Visit 2 * any history or evidence of nasolacrimal drainage system malfunction * Be planning to travel to an area significantly antigenically different for a substantial portion (more than 48 hours) of any given study week. * participation in any other investigational study within 30 days before entry into this study or concomitantly with this study * chronic or intermittent use of any prescription or over-the-counter (OTC) nasal spray during the study period